• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    M

    Mercy Health - St. Vincent Medical Center

    388论文总数
    8,322引用总数

    Mercy Health - St. Vincent Medical Center was the first hospital in Toledo, Ohio and is part of Mercy Health Partners. Mercy St. Vincent Medical Center (MSVMC), established in 1855, is the critical-care regional referral and teaching center within the Mercy Health Partners system, a seven hospital, faith-based system serving Northwest Ohio and Southeast Michigan.St. Vincent holds designations for treating high-risk mothers and babies, is a Level I Trauma Center for children & adults, and is an accredited Chest Pain Center.Through a partnership with University of Toledo Medical Center and St. Rita's Medical Center, the hospital operates both helicopter air-ambulances and ground-based critical care ambulances. .

    论文量&引用量时间轴

    机构学者

    论文(388)

    年份
    起
    –
    止
    排序
    1ABSTRACT NUMBER: ESOC2026LB146 LB146 - FINAL RESULTS OF THE DISTALS (DISTAL ISCHEMIC STROKE TREATMENT WITH ADJUSTABLE LOW-PROFILE STENTRIEVER) RANDOMIZED TRIAL OF TIGERTRIEVER 13-EVT FOR DMVO
    Jeffrey Saver,Rishi Gupta,Adrien Guenego,Adnan Siddiqui, Osama Zaidat,Muhammad Taqi, Ashutosh Jadhav, Ameer Hassan,David Liebeskind,David Fiorella,René Chapot

    Abstract Background and aims The DISTALS randomized trial evaluates the safety and effectiveness of the TIGERTRIEVER13 Revascularization Device, a radially-adjustable stent-retriever designed for deployment in distal medium vessel occlusions (DMVO). Early (24h) outcome results were presented at ISC (February-2026); full, results, including 3-month outcomes, will be presented at ESOC-2026. Methods DISTALS is a US/Europe, multicenter, prospective, randomized, blinded endpoint, FDA/IDE trial in patients ineligible for IV thrombolysis. Trial objective is to evaluate Tigertriever13 safety/effectiveness in restoring blood flow in DMVO patients presenting within 24h of onset. The primary outcome is successful reperfusion (24h/CTP) without symptomatic intracranial hemorrhage (sICH). Clinical efficacy/safety secondary outcomes include 90d global disability (mRS shift), the EQ-5D, MoCA, mortality and any ICH. Results Between May 2022 and December 2025, 149 patients were enrolled, 31 lead-in and 118 randomized. Mean age was 69 (±11); 39%-women; baseline NIHSS 7.3 (±4.5). Occlusion locations were: non-/co-dominant M2-41%; M3-25%; PCA-25%; ACA-9%. LKWT-to-randomization was 511 minutes. The primary endpoint, successful reperfusion without sICH, favored the treatment arm, 86.3% vs. 27.7%, p<0.001. sICH events were 1.6% vs 0% (p=1), ITT, with 0 sICH in randomized patients treated with Tigertriever13. The last patient 3-month follow-up will be completed in March 2026, allowing secondary outcomes results to be presented at ESOC. Conclusions Early outcome results of the DISTALS trial demonstrate that the Tigertriever13 is a safe and effective clot removal treatment strategy for DMVO patients. Clinical endpoint results will provide important additional insights into treatment outcomes. Conflict of interest

    2026European Stroke Journal(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2A234 Final Results of the DISTALS (distal Ischemic Stroke Treatment with Adjustable Low-Profile Stentriever) Randomized Trial of TIGERTRIEVER 13-EVT for DMVO
    Hannes Nordmeyer, Jeffrey Saver,Rishi Gupta,Adnan Siddiqui,Adrien Guenego,Osama O Zaidat, Asif Taqi,René Chapot,Ameer E Hassan,David Fiorella,Ashutosh P Jadhav,David S Liebeskind
    2026Abstracts(2026)
    引用
    AI阅读
    加入学术空间
    3Outpatient and Early Discharge Revision Total Joint Arthroplasty: A Systematic Review and Pooled Quantitative Analysis
    J Logan Hiatt,Zachary M Ricciardelli, Joseph M Schwab,Charlotte C Baker,Charles A DeCook,Brandon H Naylor

    Background Revision total joint arthroplasty (rTJA) volumes are rising in parallel with the rapid migration of arthroplasty to ambulatory surgery centers. Despite this shift, evidence defining the safety, outcome, and appropriate patient selection for outpatient rTJA remains limited. Methods A systematic review and pooled quantitative analysis were performed to compare inpatient and outpatient/accelerated discharge rTJA. Studies reporting patient demographics, revision types, surgical indications, comorbidities, and complications following revision total knee arthroplasty (rTKA) and revision total hip arthroplasty (rTHA) were included. There were 14 studies that met the inclusion criteria, with 11 eligible for quantitative synthesis. Results Outpatient rTKA patients were healthier, reflected by lower mean body mass index (BMI), lower mean Charlson Comorbidity Index (CCI) score, and more American Society of Anesthesiologists (ASA) classes I or II patients (91.7 versus 50.2%; P < 0.001). Outpatient rTKA patients commonly underwent less complex procedures such as polyethylene exchanges. Postoperatively, rTKA outpatients demonstrated lower or similar rates of all medical complications compared with inpatients, including periprosthetic joint infection (PJI) (9.0 versus 13.0%; P < 0.001). The outpatient rTHA cohort also had a lower mean BMI, lower mean CCI score, and more ASA classes I or II patients (73.6 versus 49.5%; P < 0.001). Outpatient hip revisions appeared to more commonly involve lower-complexity procedures, including head/liner exchanges. Reported outpatient rTHA medical complication rates were generally comparable to inpatient cohorts, although interpretation is limited by smaller sample sizes and variable reporting across studies. Notably, transfusions were lower in the outpatient rTHA cohort (6.2 versus 21.9%; P < 0.001). Conclusion In appropriately selected patients, outpatient rTKA and rTHA appear to represent a safe alternative to traditional inpatient care. These findings reinforce the importance of surgeon-driven patient selection and support the continued expansion of outpatient rTJA in the setting of evolving policy and site-of-service reform.

    2026The Journal of arthroplasty(2026)
    引用
    AI阅读
    加入学术空间
    4Paclitaxel Drug Coated Balloon Angioplasty for Medically Refractory Intracranial Atherosclerotic Disease: A U.S. Single-Center Experience with the AGENT Balloon
    Amit Chaudhari, Zachary M Rosenstein, Rashed Kamal, Niha Khan,Mohammad Almajali, Darwin Ramirez-Abreu, Jaafar Kashef Al-Ghetaa, Yazan Ashouri,Eugene Lin,Osama O Zaidat

    BACKGROUND:Intracranial atherosclerotic disease is associated with up to 10% of ischemic strokes and a high risk of recurrence. Endovascular treatments including percutaneous transluminal angioplasty and stenting have failed to demonstrate improved outcomes compared with medical therapy alone. Drug-coated balloon (DCB) angioplasty has emerged as a promising alternative, though its safety and durability remain uncertain. METHODS:This single-center retrospective study analyzed consecutive patients with refractory intracranial atherosclerotic disease treated with AGENT drug-coated balloon submaximal angioplasty. Stenosis was quantified according to the WASID criteria (Warfarin-Aspirin Symptomatic Intracranial Disease). Patients were treated either for refractory large-vessel occlusion during thrombectomy (emergency rescue) or for recurrent ischemic symptoms from high-grade stenosis (elective primary). Primary outcome was technical success, defined as <50% residual stenosis after DCB angioplasty without the need for adjunctive percutaneous transluminal angioplasty and stenting. Safety outcomes included periprocedural intracranial hemorrhage, vessel dissection, symptomatic reocclusion, ischemic stroke, and mortality at 1 month and 3 months. RESULTS:Of the 11 identified patients, 9 underwent successful DCB angioplasty, 5 for emergent rescue therapy, and 4 for elective primary therapy. There was a combined technical success rate of 78%, with no major procedural complications. Mean stenosis reduction was 53.6% (paired Wilcoxon P=0.014; preprocedure mean [SD] stenosis 90.8% [±8.6%] to postprocedure 37.3% [±33.4%]). Restenosis occurred in 3 of the 4 (75%) elective primary patients on follow-up imaging at a mean of 64 days postprocedure, without recurrent ischemic events. Follow-up angiographic data for the emergent rescue cohort was unavailable, though no symptomatic ischemic events were reported. CONCLUSIONS:Paclitaxel-coated AGENT DCB submaximal angioplasty was safe and yielded immediate improvements in luminal diameter. However, high rates of restenosis emphasize the need for innovative devices and larger prospective studies to define its therapeutic role for refractory intracranial atherosclerotic disease.

    2026Stroke (Hoboken, NJ)(2026)
    引用
    AI阅读
    加入学术空间
    5Multicenter Evaluation of the Safety and Efficacy of Varying Doses of Cangrelor Used in Acute Cerebrovascular Stenting in Patients with Acute Ischemic Stroke.
    Devin N Holden, James Spencer Dingman, Lauren H Sutton,Ciro Ramos-Estebanez,Faten El Ammar, Jirapuck Warinpramote, Raffe Siddiqui, Richard Choi, Laura Schneider, Richard Baker, Veronica Bonderski,Rami Z Morsi,

    BACKGROUND:Acute ischemic stroke often necessitates neuroendovascular interventions such as thrombectomy and, occasionally, stenting for large vessel occlusions or intracranial atherosclerotic disease. Effective antiplatelet therapy is essential during stenting to mitigate thrombosis risks, but consensus on optimal cangrelor dosing remains elusive. This study evaluates the safety and efficacy of various cangrelor doses used in acute cerebrovascular stenting. METHODS:A multicenter, retrospective cohort study was conducted across 11 comprehensive stroke centers. Patients aged 18-85 with ischemic stroke who underwent emergent cerebrovascular stenting with cangrelor were included. Patients were categorized into low-dose cangrelor (<2 mcg/kg/min; LDC) and high-dose cangrelor (≥2 mcg/kg/min; HDC) cangrelor groups. Outcomes included thrombotic and bleeding complications both intra-procedurally and within 48 hours post-procedure. RESULTS:A total of 230 patients were included in the analysis (LDC: 68; HDC: 162). Baseline characteristics were similar between groups. Thrombotic outcomes, including intraprocedural thrombosis (13% LDC vs 6% HDC; P=0.078) and thrombosis within 48 hours of the procedure (9% LDC vs 4% HDC; P=0.093), showed no statistical differences. Similarly, intraprocedural bleeding (6% LDC vs 5% HDC; P=0.753) and intracranial hemorrhage within 48 hours of the procedure (19% LDC vs 25% HDC; P=0.360) were not statistically different. CONCLUSION:Different cangrelor dosing regimens demonstrated no significant differences in thrombotic or bleeding complications during acute neuroendovascular stenting for ischemic stroke. Larger, prospective studies are warranted to refine optimal dosing strategies for cangrelor in this population.

    2026Journal of neurointerventional surgery(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 388 篇论文

    合作机构(100)

    托莱多大学合作论文 43
    埃默里大学合作论文 12
    WellStar Health System合作论文 9
    University of Toledo Medical Center合作论文 9
    克利夫兰诊所合作论文 9
    犹他大学合作论文 8
    托马斯杰斐逊大学合作论文 8
    密歇根大学合作论文 7
    弗吉尼亚大学合作论文 7
    西奈山伊坎医学院合作论文 7

    机构统计